1. Introduction {#sec0005}
===============

Porcine reproductive and respiratory syndrome (PRRS) was first reported in the United States in 1987 and subsequently in Europe in 1990 and quickly became endemic in most pig producing countries worldwide ([@bib0025], [@bib0050], [@bib0300], [@bib0415], [@bib0570]). The clinical manifestation of PRRS is complicated but is characterized by severe reproductive losses including abortions, mummified fetuses, weak born and stillborn young, post-weaning pneumonia, increased mortality, and growth retardation of young pigs. The etiological agent is PRRS virus (PRRSV). PRRSV belongs to the family *Arteriviridae* together with lactate dehydrogenase-elevating virus (LDV) of mice, equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV). By comparative genome sequence analysis, PRRSV isolates are divided into two distinct genotypes: the European type (genotype I) and North American type (genotype II), represented by Lelystad virus (LV) and VR-2332 as the prototype virus for each genotype, respectively ([@bib0025], [@bib0570]). The sequence similarities between two genotypes are approximately 60% ([@bib0005], [@bib0320], [@bib0580]). Amino acid (aa) sequence alignments indicate that the major differences between two genotypes exist in the open reading frame (ORF) 1a region and the structural protein region ([@bib0195], [@bib0305], [@bib0320]). Natural deletions and insertions are observed in some isolates, especially in the ORF1a region ([@bib0120], [@bib0160], [@bib0410], [@bib0505]).

The reverse genetics system has been developed for many RNA viruses, and infectious clones have been utilized for the study of biology and the vaccinology of viruses. The availability of such a powerful molecular tool has revolutionized the structure function studies for viral genome and proteins and has facilitated the studies for virulence, pathogenesis, immune responses, and vaccine development. The first full-length genomic cDNA clone was constructed for poliovirus more than three decades ago and its infectivity was demonstrated ([@bib0370]). Infectious clones have since been constructed for picornaviruses, caliciviruses, flaviviruses, togaviruses, influenza viruses, paramyxoviruses, rhabdoviruses, and coronaviruses to name a few ([@bib0010], [@bib0040], [@bib0365], [@bib0405], [@bib0445], [@bib0625]). For arteriviruses, EAV and PRRSV are the first for which the reverse genetics system has been developed ([@bib0270], [@bib0535]). This review will summarize our current knowledge on the principles of PRRSV infectious clones and the application to the study of arteriviruses.

2. Genome structure of PRRSV and subgenomic mRNA production {#sec0010}
===========================================================

The PRRSV genome is a single-strand positive-sense RNA of 15 Kb in length with a 5′ cap and 3′-polyadenylated tail ([Fig. 1](#fig0005){ref-type="fig"} A) ([@bib0275], [@bib0305], [@bib0320], [@bib0580]). The PRRSV genome is polycistronic and harbors two large open reading frames (ORFs), ORF1a and ORF1b, followed by ORF2a, ORF2b, and ORFs 3 through 7, plus ORF5a within ORF5 ([@bib0140], [@bib0190], [@bib0275], [@bib0305], [@bib0320], [@bib0580]). A -2 ribosomal frame-shifting has recently been identified for expression of nsp2TF in the nsp2-coding region. The nsp2TF coding sequence is conserved in PRRSV, LDV, and SHFV but absent in EAV ([@bib0135]). The coding sequences in the viral genome are flanked by the 5′ and 3′ un-translated regions (UTRs) involved in translation, replication, and transcription (see review in [@bib0420]).Fig. 1**Transcription and translation of PRRSV genome**. (A) PRRSV genome organization. PRRSV possesses a single-stranded positive-sense RNA genome of 15 kb in length with a 3′-polyadenylated tail and the 5′-cap (gray). The viral genome is polycistronic, harboring ORF1a and ORF1b, and structural genes of ORF2a, ORF2b, and ORFs 3 through 7, plus ORF5a within ORF5. (B) Viral gene expression. Non-structural proteins (black) are produced from pp1a and pp1ab after proteolytic processing. The PRRSV replicase-processing scheme involves the rapid auto-proteolytic release of nsp1α, nsp1β, and nsp2 (yellow boxes), mediated by papain-like proteinase (PLP) domains residing in each of them. The remaining polyproteins are processed by nsp4, resulting in a set of 14 individual nsps. The cleavage sites by PLPs and nsp4 are annotated by curved arrows and blue triangles, respectively. Structural proteins (color-coded) are expressed from the subset of sg mRNA. The 3′-co-terminal nested set of minus-strand RNAs is produced as a template for plus-strand sg mRNA synthesis. TRS, transcription regulatory sequence. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

ORF1a and ORF1b code for two large polyproteins, pp1a and pp1ab, with the expression of the latter mediated by the -1 frame-shifting in the ORF1a/ORF1b overlapping region ([Fig. 1](#fig0005){ref-type="fig"}B; [@bib0095], [@bib0425]). Thus, the pp1b portion is expressed always as a fusion with pp1a. The pp1a and pp1ab proteins are further processed to generate 14 non-structural proteins (nsps). The polyprotein processing scheme involves the rapid auto-proteolytic release of three N-terminal nsps, nsp1α, nsp1β, and nsp2, mediated by papain like proteinase (PLP) residing in each of them. The subsequent processing for the remaining portion of polyproteins is mediated by the serine protease in nsp4 resulting in 14 individual nsps ([@bib0090], [@bib0525], [@bib0665]). The proteolytic cleavages for individual nsps were initially predicted by sequence comparisons in combination with some experimental data from EAV, the prototype virus of the family *Arteriviridae* ([@bib0130], [@bib0665]). The exact cleavage sites for PRRSV nsp1α↓nsp1β and nsp1β↓nsp2 have recently been confirmed to be M180↓A181 and G383↓A384 mediated by PRRSV-PLP1α and PRRSV-PLP1β, respectively ([@bib0055], [@bib0470], [@bib0605]).

A set of 3′-coterminal nested subgenomic (sg) mRNAs, from which structural proteins are translated, is produced during infection ([Fig. 1](#fig0005){ref-type="fig"}B). Each mRNA contains a common 5′-end leader sequence identical to the 5′-proximal part of the genome and this sequence is referred to as transcription-regulatory sequence (TRS). The fusion of the common 5′ sequence (leader TRS) to the different 3′-body segments of sg mRNAs is mediated by discontinuous transcription which is a common strategy of nidoviruses ([@bib0400], [@bib0420], [@bib0435]). During the negative-strand sg RNA synthesis, transcription is attenuated at different body TRS regions of the genomic template. The nascent subgenome-length minus-strand RNA, having an anti-body TRS at its 3′ end, will then move and base-pair with the leader TRS and completes the extension of sg RNA. Minus-strand sg RNAs subsequently serve as a template for plus-strand sg mRNA which is subsequently translated for structural protein ([@bib0310], [@bib0400], [@bib0420]).

3. Construction of PRRSV infectious clones {#sec0015}
==========================================

The genome of negative-strand RNA viruses is non-infectious, and its replication in permissive cells requires the ribonucleoprotein (RNP) complex as the infectious unit. In contrast, the genome from positive-strand RNA viruses is fully infectious, and thus the assemly of full-length cDNA clones corresponding to the RNA genome is the kernel to the construction of infectious clones ([@bib0040], [@bib0280], [@bib0285], [@bib0445], [@bib0535]). Non-retroviral RNA viruses do not undergo a DNA intermediate step in their replication cycle. To obtain a template which can be manipulated by molecular techniques, a full-length cDNA clone is first generated using the reverse transcriptase and DNA polymerase. Once generated, two strategies have been established to generate virus progeny from the full-length copy of viral genome: RNA transfection and DNA transfection. In the RNA transfection strategy, viral RNA is synthesized by in vitro transcription using T7 or SP6 RNA polymerase coupled with the respective promoter located immediately upstream of the viral genome. The synthesized RNA genome is then introduced into cells to initiate an infection cycle. In the DNA launch strategy, a full-length genomic clone is placed under a eukaryotic promoter such as a cytomegalovirus (CMV) promoter and the entire plasmid is introduced to cells for transcription by exploiting the nuclear function of the cell. The transcribed viral genome in the nucleus is exported to the cytoplasm where viral genome translation and replication occur. This strategy omits the steps of in vitro synthesis of genomic RNA and RNA transfection, thus the risk of RNA degradation during transfection is reduced and transfection efficiency becomes consistent ([@bib0620]).

An arterivirus infectious clone was first made for EAV. The pEAV030 full-length clone containing the 12.7 kb cDNA copy of the EAV genome was infectious ([@bib0535]), and the first PRRSV infectious clone pABV437 was developed for the genotype I PRRSV Lelystad virus ([@bib0270]). Subsequently, infectious clones for VR-2332 which is the genotype II PRRSV, and the European-like genotype I PRRSV SD01-08 circulating in the US was developed ([@bib0115], [@bib0125], [@bib0340]). Numerous clones have additionally been developed including the highly-pathogenic PRRSV that emerged in China in 2006 ([@bib0165], [@bib0265], [@bib0660]). To date, at least 14 different infectious clones are available for PRRSV ([Table 1](#tbl0005){ref-type="table"} ).Table 1Construction of PRRSV infectious clone.NameYear[a](#tblfn0005){ref-type="table-fn"}Genotype[b](#tblfn0010){ref-type="table-fn"}IsolateGenBank \#Cell type forVectorPromoterGenetic marker[d](#tblfn0015){ref-type="table-fn"}ReferenceTransfectionPassagepABV414[e](#tblfn0020){ref-type="table-fn"}1998I*Ter Huurne* (TH)N/ABHK-21PAM/CL2621pOK12T7N/A[@bib0270]pABV416[e](#tblfn0020){ref-type="table-fn"}1998I*Ter Huurne* (TH)N/ABHK-21PAM/CL2621pOK12T7N/A[@bib0270]pABV4371998I*Ter Huurne* (TH)N/ABHK-21PAM/CL2621pOK12T7pacI(3′UTR)[@bib0270]N/A2003IIVR-2332AY150564BHK-21CPAM/MARC-145pOK12T7BstZ17I (ORF1a)/HpaI(3′UTR)[@bib0340]pFL122004IINVSL\#97-7895AY545985MARC-145PAM/MARC-145pBR322T7BsrGI(ORF1a)[@bib0520]pT7-P1292005IIP129AF494042MARC-145MARC-145pCR2.1T7C1559T/A12622G[@bib0230]pCMV-S-P1292005IIP129AF494042MARC-145MARC-145pCMVhCMVC1559T/A12622G[@bib0230]pSD01-082006NA I[f](#tblfn0025){ref-type="table-fn"}SD 01-08 (P34)DQ489311BHK-21PAM/MARC-145pACYC177T7ScaI(ORF7)[@bib0115], [@bib0125]pPP182006IIPrime Pac (PP)DQ779791MARC-145PAM/MARC-145pOK12T7SpeI(ORF1a)[@bib0220]pVR-V72007IIVR2332DQ217415MA-104/MARC-145MA-104/MARC-145pOK12HDV-PacIT7G7329A/T7554C[@bib0170]pWSK-DCBA2007IIBJ-4EU360128MARC-145PAM/MARC-145pWSK29SP6VspI(ORF1b)[@bib0375]pAPRRS2008IIAPRRSN/AMA-104MA-104pBluescript SK(+)T7N/A[@bib0635]pORF5M2008IIAPRRSN/AMA-104MA-104pBluescript SK(+)T7MluI (ORF5)[@bib0635]pJX1432008IIJX143EF488048MA-104MA-104pBlueScript II SK (+)T7N/A[@bib0265]pJX143M2008IIJX143N/AMA-104MA-104pBlueScript II SK (+)T7MluI (ORF6)[@bib0265]pWSK-JXwn2009IIJXwn06N/ABHK-21MARC-145pWSK29SP6BstBI(ORF1a)[@bib0660]pWSKHB-1/3.92009IIHB-1/3.9N/ABHK-21MARC-145pWSK29MSP6MluI (ORF1a)\
SifI (ORF1b)[@bib0660]pHuN4-F1122011IIHuN4-F112N/ABHK-21MARC-145pBlueScript II SK (+)SP6MluI (ORF6)[@bib0645]pACYC-VR2385-CA2011IIVR2385-CAN/ABHK-21MARC-145pACYC177T7Sph I(ORF1a)[@bib0325]pIR-VR2385-CA2011IIVR2385-CAN/ABHK-21MARC-145pIRES-EGFP2CMVSph I(ORF1a)[@bib0325]pSHE2013ISHE(AMER-VAC-PRRS/A3)GQ461593BHK-21MARC-145pB-ZJSCMVN/A[@bib0155]pCMV-SD95-212013IISD95-21KC469618BHK-21MARC-145pACYC177CMVN/A[@bib0255][^1][^2][^3][^4][^5][^6]

PRRSV infectious clones have mostly been developed based on the RNA launch strategy. BHK-21, MA-104, and MARC-145 cells are cells of choice for transfection and progeny production. Although BHK-21 cells are non-permissive for PRRSV infection, they provide a high efficiency of transfection and a good production of progeny ([@bib0270]). To eliminate the need for in vitro transcription and consistency associated with RNA transfection, the CMV promoter has been used for construction of the P129 infectious clone. The P129 virus is an isolate recovered from an outbreak of highly virulent atypical PRRS in the mid-Western USA in 1995 ([@bib0230], [@bib0620]). The CMV promoter-based infectious clone is convenient and simple to use and provides a consistency of transfection and recovery of progeny virus ([@bib0230]).

An infectious clone should genetically be identical to the parental virus. However, non-viral nucleotides are occasionally added to the viral genome at the 5′ or 3′ end to meet the engineering needs without impeding the infectivity of the clones ([@bib0270], [@bib0520]). To differentiate the reconstituted progeny virus from the parental virus, genetic markers of either restricted enzyme recognition sequences or certain nucleotide mutations have been introduced to infectious clones, and such modifications should be non-lethal and stable. To assure the starting position of the RNA polymerase II-mediated transcription, 24 nucleotides are placed between the TATA box and the genome start when constructing pCMV-S-P129 ([@bib0230]). The PRRSV genome is usually divided to several fragments flanked by restriction sites for subsequent assembly ([@bib0270], [@bib0340]). As a cloning vector, a low-copy-number plasmid is generally preferred as suggested in some studies ([@bib0270], [@bib0460], [@bib0340]) but has appeared unnecessary. Progeny virus generated from an infectious clone should ideally retain the biological properties of the parental virus, such as growth rate, virulence, and transmissibility ([@bib0225], [@bib0230], [@bib0270], [@bib0340], [@bib0520], [@bib0635]).

4. Engineering PRRSV infectious clones {#sec0020}
======================================

Like most RNA viruses, PRRSV genome has evolved to optimal fitness, and most of the genetic information seems to be essential ([@bib0540]). Notably, the 3′-proximal portion of the genome is compact and organized to contain eight genes, most of which overlap with neighboring genes ([@bib0420]). The PRRSV genome is complex and the engineering of such a compact viral genome is a challenge. In addition, minor alternations in conserved regions or functional domains in the genome almost inevitably lead to non-viable consequences ([@bib0015], [@bib0215], [@bib0230]). Despite such difficulties, some genetic manipulations for PRRSV have been successful.

4.1. Strategies for infectious clone engineering {#sec0025}
------------------------------------------------

Mutation, deletion, insertion, and substitution are major approaches to viral genome manipulation. Due to the large genome of PRRSV, shuttle plasmids have been used as an intermediate platform to contain the target viral genomic sequence with a pair of unique enzyme sites at each end. Mutations are introduced to target sites or sequences in the shuttle plasmid. The biological functions of PLP1α and PLP1β in nsp1, conserved cysteine residues at C49 and C54 in the E protein, N-linked glycosylation sites in GP3 at N131 and GP5 at N34, N44, and N51, cysteines at C23, C75, and C90 for homo-dimerization of N protein, and the motif for nuclear localization signal (NLS) of N have been mutated to produce PRRSV mutants ([@bib0015], [@bib0215], [@bib0230], [@bib0235], [@bib0240], [@bib0360], [@bib0555]). Alanine scanning and protein surface accessibility predictions were conducted for identification of residues for type I IFNs or TNF-α antagonism of nsp1, and specific residues have been mutated in the infectious clones ([@bib0035], [@bib0255], [@bib0455]). Mutations have also been introduced to knockout genes by changing the translation initiation codon, and this approach destroys the expression of nsp1 and E protein ([@bib0245], [@bib0515]).

Deletion of genomic sequences has been applied to identifying non-essential regions for PRRSV replication or to obtaining attenuated live vaccine candidates ([@bib0540]). Inter-genotypic sequence alignments between genotype 1 and genotype 2 reveal the regions of sequence heterogeneity suggesting the potential to tolerate the deletions, and non-essential regions in the N gene and 3′-UTR ([Table 2](#tbl0010){ref-type="table"} ; [@bib0485], [@bib0490]). The hypervariable regions have been observed in the nsp2 gene ([@bib0120], [@bib0160], [@bib0330], [@bib0410], [@bib0505]), suggesting the existence of a non-essential region in nsp2 ([@bib0060], [@bib0170], [@bib0375], [@bib0600]b). Deletion of ORF2 or ORF4 results in the absence of infectivity, suggesting the requirement of GP2 and GP4 proteins for PRRSV infectivity ([@bib0565]).Table 2Identification of non-essential regions of PRRSV genome.Genotype and geneMutation/deletion (nts or aa)MotifInfectious cloneGrowth[d](#tblfn0040){ref-type="table-fn"}GenBankII5′UTR1--3 ntsN/ApAPRRSN/AGQ330474.2IInsp213--35 aahypervariablepVR-V7↓DQ217415IInsp2324--726 aahypervariablepVR-V7↓DQ217415IInsp2727--813 aahypervariablepVR-V7↓DQ217415IInsp2480--667 aahypervariablepHuN4-F112N/AEF635006Insp2691--722 aaES3[a](#tblfn0030){ref-type="table-fn"}pSD01-08↑DQ489311Insp2736--790 aaES4[a](#tblfn0030){ref-type="table-fn"}pSD01-08ncDQ489311Insp21015--1040 aaES7[a](#tblfn0030){ref-type="table-fn"}pSD01-08↓DQ489311IIORF75--13 aaN/ApAPRRS↓GQ330474.2IIORF739--42 aaN/ApAPRRS↓GQ330474.2IIORF748--52 aaN/ApAPRRSncGQ330474.2IIORF7120--123 aaN/ApAPRRSncGQ330474.2IIORF743,44 aaNLS[b](#tblfn0035){ref-type="table-fn"}pCMV-S-P129↓AF494042IIORF743,44,46 aaNLS[b](#tblfn0035){ref-type="table-fn"}pCMV-S-P129↓AF494042IIORF746,47 aaNLS[b](#tblfn0035){ref-type="table-fn"}pCMV-S-P129↓AF494042IORF7123--128 aaN/ApABV437ncN/AI3′UTR14989--14995 ntsN/ApABV437ncN/AII3′UTR15370--15409 ntsN/ApAPRRSN/AGQ330474.2[^7][^8][^9][^10]

Insertion of additional nucleotides to the viral genome expands the scope of modifications. An attempt was made to separate overlapping regions of PRRSV structural protein genes, and three restriction enzyme sites were inserted between ORFs 5/6 and ORFs 6/7 ([@bib0630]), which produced viable viruses. The possibility of expressing foreign genes using PRRSV has been explored; the nsp2 gene was utilized as an insertion site for expressions of green fluorescent protein (GFP) and FLAG tag ([@bib0125], [@bib0200]). An alternate approach was taken to insert foreign genes within a structural gene; for example, a small portion of the influenza virus hemagglutinin (HA) gene into the 5′ or 3′ end of ORF7 of PRRSV ([@bib0045]). However, the insertion of HA to N gene resulted in a nonviable virus. A strategy utilizing the mechanism of transcription of PRRSV for foreign gene expression is of particular interest. Using an infectious clone, two unique enzyme sites have been introduced between ORF1b and ORF2, and a copy of the TRS6 sequence was inserted to replace the TRS designed to synthesize the mRNA for foreign gene expression ([Fig. 4](#fig0020){ref-type="fig"}) ([@bib0230], [@bib0360], [@bib0620]). The foreign genes including GFP, capsid protein of porcine circovirus type 2 (PCV2), *Discosoma* sp. (sea anemone) red fluorescent protein (DsRED), Renilla luciferase (Rluc), IFN-α1, IFN-β, IFN-δ3, and IFN-ω5 have all been expressed as an independent transcript using this approach ([Table 3](#tbl0015){ref-type="table"} ; [@bib0360], [@bib0395]).Table 3Insertion tolerable regions in PRRSV genome.GenotypeGenomic regionPositionForeign sequenceInfectious cloneGrowth rate[a](#tblfn0045){ref-type="table-fn"}GenBankntaaIIORF1ansp23219/3220N/AGFPpCMV-S-P129ncAF494042IIORF1ansp23219/3220N/AFLAG-tagpCMV-S-P129↓AF494042IIORF1ansp23614/3615N/AGFPpCMV-S-P129↓AF494042IORF1ansp2N/A348/349GFPpSD01-08↓DQ489311IIORF1ansp2N/A507/508B-cell epitope in NDV NPpSK-F112-D508--532ncN/AIIORF1b/ORF2N/AN/ATRS6 + GFPpCMV-S-P129ncAF494042IIORF1b/ORF2N/AN/ATRS6 + PCV2 CpCMV-S-P129ncAF494042IIORF1b/ORF2N/AN/ATRS6 + DsREDpCMV-S-P129ncAF494042IIORF1b/ORF2N/AN/ATRS6 + RlucpCMV-S-P129ncAF494042IIORF1b/ORF2N/AN/AIFNα1pCMV-S-P129↓AF494042IIORF1b/ORF2N/AN/AIFNβpCMV-S-P129↓AF494042IIORF1b/ORF2N/AN/AIFNδ3pCMV-S-P129ncAF494042IIORF1b/ORF2N/AN/AIFNω5pCMV-S-P129↓AF494042IIORF1b/ORF2N/AN/AAscI,SwaI, PacIpAPRRSncGQ330474.2IIORF4/ORF5N/AN/ANdeIpAPRRSncGQ330474.2IIORF5/ORF6N/AN/AAscI,SwaI, PacIpAPRRS↓GQ330474.2IIORF6/ORF7N/AN/AAscI,SwaI, PacIpAPRRSncGQ330474.2IIORF7/3′UTRN/AN/ANdeIpAPRRSncGQ330474.2[^11][^12]

Multiple genes, a single gene, or partial sequence of the viral genome have been substituted with corresponding sequences from other arteriviruses for chimeric arterivirus construction. The first chimeric arterivirus was generated using an EAV infectious clone as a backbone, and ectodomains of two membrane proteins, GP5 and M, were substituted with the corresponding sequences from PRRSV or LDV ([@bib0105]). These chimeric viruses were viable, and additional chimeric arteriviruses have been constructed ([Table 4](#tbl0020){ref-type="table"} ). The construction of intra- or inter-genotypic PRRSV chimeras is maneuverable, and the regions of 5′-UTR, non-structural genes, and structural genes have been replaced ([@bib0155], [@bib0260], [@bib0500], [@bib0495], [@bib0555], [@bib0660]). To facilitate the intra-genotypic substitution, a gene-swapping mutagenesis technique has been used to substitute the structural genes ([@bib0210]). Using this technique, individual replacement of ORF2a and ORF2 through ORF6 of VR-2332 was successfully carried out with corresponding ORFs from other strains of PRRSV including JA142, SDSU73, PRRS124, and 2M11715 ([@bib0210]).Table 4Constructions of chimeric viruses.Swapped region[a](#tblfn0050){ref-type="table-fn"}Substituent[b](#tblfn0055){ref-type="table-fn"}ViabilityVirusStrainInfectious clone[c](#tblfn0060){ref-type="table-fn"}Genome regionPosition aaVirusStrainGenome regionPosition aaEAVBucyruspA45ORF51--114LDVPGP51--64+PRRSVIAF-KlopGP51--64+SHFVLVR 42--0/M6941GP71--138−SinVSan JuanE11--428−VSVHRG1--402−WholeEAVA45-80.4GP5Whole+5rUCDGP5Whole+5r6D10GP5Whole+5rVACGP5Whole+5rKY84GP5Whole+5rIL93GP5Whole+5rCA95GP5Whole+5rWA97GP5Whole+5rATCCGP5Whole+5r10B4GP5Whole+ORF617--162PRRSVIAF-KlopM1--16−LDVPM1--14−ARVACprMLVB4/5ORF5115--255PRRSVIA-1107ORF51--64+prMLVB4/5ORF5N/A^d^PRRSVIA-1107ORF5Whole−prMLVB5/6ORF6N/A^d^PRRSVIA-1107ORF6Whole−prMLVB4/5/6ORF617--162PRRSVIA-1107ORF61--17+  PRRSVLVpABV437ORF61--16PRRSVV2332M1--16−LDVPM1--14+EAVBucyrusM1--17−pABV871ORF61--16PRRSVV2332M1--16+EAVBucyrusM1--17+VR2332N/AORF2WholePRRSVJA142ORF2Whole+ORF3WholePRRSVJA142ORF3Whole+1--194PRRSVJA142ORF31--194+183--255PRRSVJA142ORF3183--255+ORF4WholePRRSVJA142ORF4Whole+ORF5WholePRRSVJA142ORF5Whole+SDSU73ORF5Whole+2M11715ORF5Whole+PRRS124ORF5Whole+ORF6WholePRRSVJA142ORF6Whole+ORFs5-6WholePRRSVJA142ORFs5-6Whole+ORFs4-6WholePRRSVJA142ORFs4-6Whole+ORFs3-6WholePRRSVJA142ORFs3-6Whole+ORFs2-6WholePRRSVJA142ORFs2-6Whole+APRRSpAPRRS\
ascORFs2a-4WholePRRSVSHEORFs2a-4Whole+EAVvEAV030ORFs2a-4Whole+ORFs2a-5WholePRRSVSHEORFs2a-5Whole+ORF5WholePRRSVSHEORF5Whole+NVSL\# 97--7895FL12ORFs2a-7WholePRRSVPRRSV01ORFs2a-7Whole+[^13][^14][^15][^16]

4.2. Identification of modification-limited genomic regions {#sec0030}
-----------------------------------------------------------

### 4.2.1. nsp2 {#sec0035}

PRRSV nsp2 is a multifunctional protein that undergoes remarkable genetic variations. The nsp2 protein consists of five regions: hypervariable region I (HV-I), PLP2 cysteine protease core, hypervariable region II (HV-II), transmembrane regions, and a C-terminal tail ([Fig. 2](#fig0010){ref-type="fig"} A; [@bib0175]). The PLP2 cysteine protease domain possesses cis-acting and trans-acting cleavage activities and mediates its rapid release from pp1a and pp1ab ([@bib0175], [@bib0430]). Two sites were initially predicted for nsp2/nsp3 cleavage at 981G/982G and somewhere at 1196G/1197G/1198G, and recent studies showed the actual cleavage occurs at 1196G/1197G for VR-2332 ([@bib0005], [@bib0175], [@bib0320]). The corresponding cleavage for EuroPRRSV SD01-08 likely occurs at 1445GG/1447A ([@bib0130]). PLP2 is as a member of the ovarian tumor domain (OTU) family of deubiquitinating enzymes, and has shown to deconjugate ubiquitin (Ub) and IFN-stimulated gene (ISG) 15 from cellular targets. This is an important viral strategy inhibiting the Ub-dependent and ISG15-dependent host innate immune responses ([@bib0145], [@bib0475], [@bib0480], [@bib0530])Fig. 2**Engineering of infectious clones for nsp2 region.** (A) Schematic presentation of the nsp2 protein. The nsp2 protein consists of five regions: hypervariable region I (HV-I), PLP2 cysteine protease core, hypervariable region II (HV-II), transmembrane regions, and the C-terminal tail. White areas indicate natural deletions. A triangle indicates the position of natural insertion. (B) Location of experimental sequence deletions (Orange). (C) Foreign gene insertion sites. Triangles indicate the position of insertion. GFP, green fluorescent protein; HV, hypervariable region; PLP, papain-like proteinase. Numbers indicate amino acid positions of nsp2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Besides the proteinase and deubiquitinase functions, nsp2 contributes to the major genetic differences between genotypes I and II, sharing only less than 40% similarity at the amino acid level ([@bib0005], [@bib0320]). The nsp2 gene also contains naturally inserted sequences and deletions ([Fig. 2](#fig0010){ref-type="fig"}A) in the hypervariable region ([@bib0120], [@bib0160], [@bib0325], [@bib0410], [@bib0505]). The deletion of 12 amino acids in nsp2 was first found in a Chinese PRRSV isolate, HB-2(sh)/2002, in comparison with other North American isolates ([@bib0160]). Sequence analysis of PRRSV MN184 reveals three discontinuous deletions of 111, 1, and 19 amino acids at the corresponding positions 324--434, 486, and 505--523 of VR-2332, respectively ([@bib0180]). Discontinuous deletions were also identified in the highly pathogenic PRRSV (HP-PRRSV) associated with the 2006 outbreaks of porcine high fever disease in China ([@bib0505]). The 30 amino acids discontinuous deletion consists of 1 aa deletion at position 482 and 29 aa deletions at 534--562, and the deletion region contains B-cell epitopes ([@bib0075]) and T-cell epitopes ([@bib0060]). Strikingly, cell culture passages of PRRSV may generate a deletion in nsp2, and a study shows the generation of a large deletion of 135 aa at 581--725 in nsp2 during passages ([@bib0325]). A deletion in nsp2 is also found in genotype I PRRSV. The EuroPRRS SD-01-08 virus in the US shows a 17 aa deletion at positions 349--365 of nsp2 when compared to Lelystad virus ([@bib0120]). Biological significance of the genetic deletion in nsp2 remains to be determined. Besides deletions, a 36 aa insertion was also observed in the SP strain of PRRSV, which is a vaccine strain, located between G812 and T849 of the SP nsp2 ([@bib0410]).

Given the tolerance of deletions and insertions in the hypervirable region of nsp2, this region is considered as a site for foreign gene insertion ([Fig. 2](#fig0010){ref-type="fig"}B and C). The GFP gene was inserted into nsp2 of the SD01-08 strain and fully infectious virus was rescued ([@bib0125]). The GFP insertion did not affect the growth of the virus, and the infectivity was comparable to that of parental virus. The capacity of deletion in nsp2 was determined by introducing a series of in-frame deletions ([@bib0170]). The PLP2 domain, the PLP2 downstream flanking region, and the transmembrane domain were crucial for virus replication but deletions of 13--35 aa from the N-terminal portion of the hypervariable region and 324--813 aa from the hypervariable region appeared to be tolerable for viability. In the hypervariable region, the largest deletion that can be achieved was about 400 aa at positions 324--726, although a deletion of up to 200 aa is preferable for infectivity ([Fig. 2](#fig0010){ref-type="fig"}B). The insertion of GFP or other genes such as New Castle disease virus nucleoprotein (NP) gene has been successful as long as insertions reside in the hypervirable regions ([Fig. 2](#fig0010){ref-type="fig"}C) ([@bib0200], [@bib0595]). The deletion of inmmunodominant linear B-cell epitopes (ES2-ES7) were attempted; deletion of ES3, ES4, or ES7 allowed the generation of an infectious virus ([@bib0060], [@bib0345]).

### 4.2.2. N protein {#sec0040}

PRRSV N is a mutilfunctional protein. The specific domains and residues critical for virus replication have been identified in N ([Fig. 3](#fig0015){ref-type="fig"} A). The N protein is comprised of 123 or 128 aa for the North American and European genotypes, respectively ([@bib0310]). N consists of the N-terminal RNA-binding domain (RBD) at positions 41--47 and the C-terminal dimerization domain comprising a four-stranded antiparallel β-sheet floor flanked by α-helices ([@bib0100], [@bib0615]). As the sole component of viral capsid, N interacts with itself via covalent or noncovalent interactions ([@bib0100], [@bib0590]). The cysteine at position 23 is responsible for the formation of an intermolecular disulfide bond, and aa 30--37 are essential for mediating noncovalent homodimers ([@bib0590]). A crystallographic study on N shows the imprtance of the C-terminal dimerization domain for N ([@bib0100], [@bib0450]). PRRSV N is a serine phosphoprotein which is a common property for N of EAV and coronaviruses ([@bib0310], [@bib0585]). One of the phosphorylation sites of N is at position 120, but its biological significance is still unknown. N contains NLS in a stretch of basic amino acids 41-PGKKNKK-47 which is overlapping with the RNA-binding domain and particially with a nucleolar localization signal (NoLS) at aa 41--72 ([@bib0380], [@bib0385]). The nuclear export signal (NES) is found at positions 106--117 and is responsible for the nucleolar-cytoplasmic shuttling of N ([@bib0390]).Fig. 3**Engineering of infectious clones in N gene.** (A) Schematic presentation of the nucleocapsid (N) protein. NLS and RBD overlap each other. (B) Deletion tolerance regions (yellow) in N protein. NLS, nuclear localization signal; NES, nuclear export signal; P, phosphorylation site; S, disulfide bridge, RBD, RNA-binding domain; NoLS, nucleolar localization signal. NCI, non-covalent interaction motif. Numbers indicate amino acid positions of N. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

The functional structure of N is compact and thus N is sensitive to structural modification. The secondary structure in the C-terminal residues 112--123 is an important determinant for conformational epitopes, and the mutations in this region change the monoclonal antibody (MAb) reactivity ([@bib0575]). Insertion of a foreign sequence into the N gene was attemped and the influenza virus HA epitope was added at the N-terminus or C-terminus. Despite the initial rescue of the infectious virus, the HA expression was unsuccessful ([@bib0045]). The GFP tag was inserted between ORF6 and ORF7 to moniter the ORF7 mRNA synthesis, but no mRNA was made, indicating the 5′ end of the ORF7 gene is essential for mRNA synthesis ([@bib0620]). The N protein is inter-genotypically conserved but shares only 60% of its identity between LV and VR-2332 ([@bib0085]). The C-terminus of N is heterogenous, and truncation of up to 6 aa is tolerable ([@bib0540]). In another study, deletions were made at the inter-genotypic variable region or conserved region of N, and 4 regions at 5--13, 39--42, 48--52, and 120--123, were found to be dispensible for viability ([Fig. 3](#fig0015){ref-type="fig"}B) ([@bib0490]). No foreign gene can be incorporated in these rgions. Fig. 4**PRRSV infectious clone for foreign gene expression.** A copy of TRS (Black bar) is inserted between ORF1b and ORF2. Two kinds of sg mRNAs are produced from this construction. The GFP or other foreign genes is inserted between the synthetic TRS (Black bar) and the original TRS (Brown bar), and the original TRS leads to generation of mRNA for GFP expression. The inserted TRS drives the synthesis of sg mRNA for ORF2 expression. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

### 4.2.3. Non-conding regions {#sec0045}

The PRRSV genome is flanked by 5′- and 3′-UTR, and the UTR sequences play a vital role for genomic replication, mRNA transcription, and protein translation ([@bib0350], [@bib0420]). The non-coding regions of the genome have been investigated. By serial deletions, the first 3 nucleotides in 5′-UTR appears to be dispensible for viability in type II PRRSV ([@bib0150]). For 3′-UTR, the first 11 nucleotides are unique for each genotype, and a stretch of 38 nucleotides is present in VR-2332 but is absent in LV ([@bib0005], [@bib0540]). A deletion study shows that 7 nucleotides at the 5′ end of the 3′-UTR is tolerable for genotype I PRRSV ([@bib0540]). The 3′-UTR of genotype II has also been studied, and at least 40 nucleotides immediately following ORF7 is dispensable for virus viability ([@bib0485]).

The genetic information on the structural region of arteriviruses is organized in an extremely efficient manner. The genes for GP2, GP3, and GP4 overlap each other, and similarly the genes for GP5, M, and N overlap each other for PRRSV. This structural complexicity hampers the genetic manipulation of infectious clones. The importance of the overlapping gene arrangement for the life-cycle of virus has been studied ([@bib0545], [@bib0630]). A series of full-length clones were engineered to separate overlapping genes for EAV ORFs 4/5 or ORFs 5/6 by inserting small additional sequences containing a termination codon for the upstream gene, a unique restriction site, and a translation initiation codon for the downstream gene. The insertions result in the functional separation of overlapping ORFs, and do not impair infectivity ([@bib0080]). The ORFs 5/6 separation in genotype I PRRSV is also possible and progeny virus is produced ([@bib0545]). For the North American PRRSV, restriction sites were inserted between ORFs 1/2, ORFs 4/5, ORFs 5/6, ORFs 6/7, and ORFs 7/3′-NTR, and progeny viruses are generated from these modifications. This indicates that gene overlap is dispensable for infectivity and that separation of each gene does not interrupt mRNA synthesis ([@bib0630]).

5. Applications of PRRSV infectious clone {#sec0050}
=========================================

5.1. Chimeric viruses and cell tropism {#sec0055}
--------------------------------------

The development of infectious clones allows the construction of chimeric arteriviruses. An attempt was made to swab the ectodomains of GP5 and M. In engineered chimeric viruses using the EAV clone as a backbone, the ectodomains were replaced by corresponding sequences from other arteriviruses. Chimeric viruses containing the GP5 ectodomain from LDV and PRRSV were infectious. These chimeric viruses however retain their cell tropism for BHK-21 cells, which are susceptible for EAV but non-susceptible for LDV and PRRSV ([@bib0105]). Replacement of the M ectodomain of EAV with the corresponding sequence from other arteriviruses does not produce infectious virus, but replacement of the M ectodomain of PRRSV with the corresponding sequence from LDV, EAV, and genotype II PRRSV produced an infectious virus. Using the LV infectious clone as a backbone, substitutions with the EAV M ectodomain or VR-2332M ectodomain is impossible, but removal of the gene overlap between the M and GP5 genes is required before swapping, indicating that the VR-2332M ectodomain and EAV M ectodomain are incompatible with the remaining part of LV M. It is also possible that unintended mutations may have been introduced to GP5 during the ectodomain swap ([@bib0545]). Substitution of structural genes between arteriviruses has been extremely useful to identify viral factors for viral tropism. The substitution of GP5 or/and M do not alter their cell tropism ([@bib0105], [@bib0260], [@bib0545]). In contrast, the substitution of minor envelope proteins and E protein using the PRRSV infectious clone as a backbone allows the chimeric PRRSV to acquire a broad cell tropism but to lose the ability to infect PAMs. It indicates that the GP2/GP3/GP4 minor proteins are determinants for cell entry and tropism ([@bib0500]).

5.2. Chimeric viruses and virulence immunogenicity {#sec0060}
--------------------------------------------------

Intra-genotypic or inter-genotypic gene-swapping have been conducted between EAV and PRRSV to study the genetic compatibility and viral-specific phenotypes, including neutralization, virulence, and pathogenesis. For neutralization, 9 chimeric EAVs were generated in which each construct contained individual ORF5 from different isolates ([@bib0020]). Also, the role of individual envelope proteins of GP2 through M for cross-neutralization was studied using the VR-2332 infectious clone as a backbone ([@bib0210]). The PRRSV-01 strain is highly susceptible to serum neutralization and induces atypically rapid and robust neutralizing antibodies in pigs. Analysis of structural genes of PRRSV-01 reveals the absence of two N-linked glycosylation sites each in GP3 and GP5. The significance of missing glycans for neutralization has been determined by replacing GP3 and GP5 genes from PRRSV-01 ([@bib0555]). The major virulence determinants have also been identified by gene swapping experiments to locate in nsp3 through nsp8 and GP5 ([@bib0225]). Highly pathogenic PRRSV contains the 30 aa deletion in nsp2 sequence ([@bib0505]). By gene swapping studies using nsp2 from an avirulent PRRSV, the deletion in nsp2 was shown to be irrelevant to virulence and pathogenicity ([@bib0660]). A recent study identified nsp9- and nsp10-coding regions together were essential for increased pathogenicity and fatal virulence for HP-PRRSV by swapping these regions between the highly and low pathogenic strains ([@bib0250]). The inter-genotypic 5′-UTR swap between genotypes I and II was investigated and shows that the 5′-UTR of genotype II may be substituted with the corresponding sequence from genotype I, while the substitution of 5′- UTR of genotype I with its corresponding sequence from genotype II is lethal ([@bib0155]). Using this approach, the envelope proteins representing GP2 through GP5 of genotype I are shown to be fully functional for genotype II when using genotype II as a backbone ([@bib0500]).

5.3. Rational design for a new PRRS vaccine {#sec0065}
-------------------------------------------

A random sequence shuffling has been employed to generate immunologic variants of PRRSV ([@bib0330], [@bib0655], [@bib0650]). GP3 sequences representing immunologically diverse strains of PRRSV are randomly shuffled, and the shuffled gene is incorporated in the infectious clone to generate a new virus that contains a new GP3 gene, which may improve the cross neutralization ([@bib0655]). The breeding of GP4 and M have also been tried, and the rescued virus induces a broad spectrum of cross-neutralizing antibodies ([@bib0650]). The GP5 sequence from 7 genetically diverse strains of PRRSV and the GP5-M sequence from 6 different strains were subjected to breeding, and the shuffled genes were cloned in infectious clones for the generation of new viruses. Two representative chimeric viruses, DS722 by GP5 shuffling and DS5M3 by GP5-M shuffling, were found to be clinically attenuated ([@bib0330]). This approach allows rapid generation of an attenuated virus and may be useful for vaccine development for antigenetically variable viruses ([@bib0330], [@bib0655]). Another approach to the rapid generation of attenuated PRRSV is referred to as SAVE (synthetic attenuated virus engineering). Codon-pair bias is a phenomenon that certain codon pairs appear in a higher frequency in comparison to other synonymous codon pairs for the same amino acid, and the codon-pair bias is host species-dependent related to the efficiency of protein synthesis ([@bib0065], [@bib0290], [@bib0295]). By deoptimizing the codon pair of a virulence gene, an expression level of this protein decreases. The computer-aided deoptimization of codon-pairs modifies only naturally optimized pairs of codons and does not change the amino acid sequence ([@bib0295]). Using this approach, the GP5 gene was codon-pair deoptimized, and a new virus was generated. The modified GP5 sequence did not affect the viability of PRRSV and the engineered virus was clinically attenuated in pigs ([@bib0335]).

To fulfill serological discrimination between naturally infected and vaccinated animals, removing an immunodominant epitope has been applied to developing a live-attenuated differentiating infected from vaccinated animals (DIVA) vaccine against PRRSV ([@bib0070], [@bib0550]). The serologic marker antigen selected for DIVA vaccine should be highly immunodominant without disrupting protective well-conserved epitopes among PRRSV isolates and stability during passages. Besides, the removal of a selected epitope should not adversely affect the growth property or virulence of the mutant virus ([@bib0070], [@bib0550]). Two epitopes residing in nsp2 and M have been identified fulfilling the requirements for PRRSV DIVA vaccine ([@bib0070], [@bib0550]). Two mutants, FLdNsp2/44 with a deletion of residues 431--445 within nsp2, and Q164R disrupting antigenicity of epitope M201 in M protein have been designed and constructed accordingly ([@bib0070], [@bib0550]). The immunogenicity of those two epitopes has been eliminated during infection of PRRSV mutants, and both epitopes may be used as an immunologic marker for DIVA vaccine development ([@bib0070], [@bib0550]).

5.4. PRRSV as a foreign gene expression vector {#sec0070}
----------------------------------------------

PRRSV may serve as a vaccine vector. PRRSV infectious clones have been developed as a gene delivery vector for foreign gene expression. Identification of gene insertion sites in the viral genome and viral infectivity is critical for gene delivery. GFP and B-cell epitopes of the Newcastle disease virus (NDV) nucleoprotein have been inserted into non-essential regions of nsp2 of PRRSV ([@bib0125], [@bib0110], [@bib0200], [@bib0595]). In this approach however, the stability of the inserted gene was of a concern. When PRRSV expressing GFP in nsp2, PRRSV SD01-08-GFP, was cell-culture passaged, a population of GFP-expression negative-virus appears by the 7th passage. Sequencing shows a deletion of GFP at the N-terminal half (1 to 159), leading to the loss of GFP expression. Insertion of 2 amino acids at position 160 of GFP was also observed in some viral clones ([@bib0125]). The stability of the GFP gene in this recombinant virus was improved by deleting the ES4 epitope located downstream of the GFP gene, and the GFP expression in this virus was stable for 10 passages. However, R97C mutation was found in GFP, and this mutation caused the loss of florescence ([@bib0110]). The loss of fluorescence was also observed in two other GFP recombinant viruses during serial passages. In another study, the GFP-coding sequence remained intact but point mutations were identified and these mutations caused amino acid changes to R96C and N106Y ([@bib0200]). The expression of 49 aa B-cell epitope of the NDV nucleoprotein in PRRSV nsp2 remained stable in cell culture up to 20 passages ([@bib0595], [@bib0645]). The instability of foreign gene insertion in nsp2 is not fully understood. The length of insertion may be important for stability.

An attempt was made to produce an additional mRNA for foreign gene expression. The GFP gene was inserted between ORF1b and ORF2a for PRRSV along with a copy of TRS ([@bib0230], [@bib0360], [@bib0395], [@bib0620]). Compared to insertion in nsp2, this site is suitable for foreign gene insertion since the recombinant virus was stable for up to at least 37 passages without the loss of gene or fluorescence ([@bib0360]). The genetic stability of genes inserted at this site has been confirmed by expressing other genes including DsRed, Renilla luciferease, IFNα1, IFNβ, IFNδ3, and IFNω5 ([@bib0395]). This approach has the particular advantage of eliminating the need to alter the coding sequence of a viral gene and also of minimizing the effects on expression and post-translational modification of viral proteins ([@bib0360]).

5.5. Application of infectious clones to structure function studies {#sec0075}
-------------------------------------------------------------------

Infectious clones are important molecular tools to study structure function relationships of proteins and genomic sequences at the infectious virus level in vivo. Specific sequence motifs may be mutated or deleted from the virus and their phenotypes may be examined to determine their functions. The removal of N-linked glycosylation at N34 and N51 of GP5 results in a mutant virus with its phenotype of enhanced sensitivity to serum neutralization and high level induction of neutralizing antibodies ([@bib0015]). Elimination of N44-linked glycan is not in concert with a high-level neutralizing antibody response to wild type PRRSV ([@bib0560]). Meanwhile, introduction of multiple mutations at these N-linked glycosylation sites could significantly reduce virus yields ([@bib0560]). The E gene knock-out mutation allows for genome replication and transcription but does not produce infectious progeny, indicating that the E protein is essential for virion assembly ([@bib0245]). PRRSV nsp1 is a multifunctional protein regulating the accumulation of genomic RNA and mRNAs. It also has the ability to modulate the host innate immunity by suppressing the type I IFN production ([@bib0315], [@bib0465]a; [@bib0610]). The motifs for zinc fingers, PLPs, and nuclease have been identified in nsp1 ([@bib0130], [@bib0420], [@bib0605]). By deleting from the genome, nsp1 is shown to be dispensable for genome replication but crucial for mRNA transcription. Mutation in the catalytic sites of PLP1 impairs both viral genome and mRNA synthesis as well as the cleavage between nsp1 and nsp2. Mutations in the zinc finger motif abolished the mRNA transcription, whereas genome replication was not affected ([@bib0515], [@bib0510]). When the catalytic sites of PLP1α are mutated using a PRRSV infectious clone, the proteinase activity disappears and mRNA synthesis is completely blocked. In contrast, mutations at the PLP1β catalytic sites result in no mRNA synthesis and no viral infectivity, indicating that the normal cleavage of nsp1 and nsp2 is critical for viral replication ([@bib0215]).

To design effective vaccine candidates that may be useful to overcoming antigenic heterogeneity of PRRS, extensive studies have been conducted to eliminate the IFN antagonistic function from the virus (see reviews [@bib0420], [@bib0465]a; [@bib0610]). Among viral proteins, nsp1α and nsp1β have been identified as potent IFN analogists ([@bib0030], [@bib0055], [@bib0185], 2014; [@bib0205], [@bib0440]). Subsequent studies have identified specific residues regulating the IFN antagonism, and a mutant virus with a stretch of alanine substitution at positions 16--20 of nsp1β showed the loss of IFN suppression ([@bib0035]). In another study, K124 and R128 were mutated to release the surface accessibility of nsp1β, and mutant PRRSV impaired the IFN antagonism ([@bib0255]).

Motifs in the N protein have broadly been studied using mutant viruses. The importance of N protein dimerization has been examined by mutating C23S which is responsible for the covalent interaction between N proteins. Mutant viruses of C23S, C75S, and C90S were constructed, and with the exception of C75S, both C23S and C90S completely lost their infectivity. In another study however, the replacement of cysteines within N protein, either singly or in combination, did not impair the growth PRRSV according ([@bib0640]). Genome replication and mRNA transcription were normal for both mutants, suggesting the dimerization of N may be important for particle assembly or maturation ([@bib0230]). The nuclear localization signal (NLS) of N was also mutated to examine the biological consequence of N in the nucleus in PRRSV-infected cells. Compared to wild-type PRRSV, NLS-null mutant PRRSV was attenuated in pigs and produced a significantly shorter mean duration of viremia and higher titers of neutralizing antibodies ([@bib0235], [@bib0355]), demonstrating that the N protein nuclear localization is a virulence factor.

6. Conclusions {#sec0080}
==============

As an emerged and re-emerging disease in swine, PRRS has extensively been studied for molecular biology, immunology, and prevention. The unusual immune responses in pigs and antigenic heterogeneity of the virus are two main obstacles to developing a satisfactory PRRS vaccine. The availability of PRRSV infectious clones and recent advances in recombinant DNA technology have made possible to manipulate the viral genome to introduce specific mutations to targeted sequences and to create genetically modified mutant viruses. Extensive efforts have been applied to making mutant viruses with modified phenotypes of immune responses including the evasion of neutralizing antibodies and suppressed innate immune responses. For viral heterogeneity, the RNA-dependent RNA polymerase (RdRp) is believed to cause frequent mutations in the PRRSV genome. Genetic swapping or modifications of nsp9, the RdRp of PRRSV, may be studied to make mutant viruses with reduced mutation rates during replication. The reverse genetics of PRRSV is a powerful genetic tool and has the potential to apply to the basic understanding of the biology of PRRSV and to the development of genetically modified vaccines and gene delivery.
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[^1]: N/A, not application.

[^2]: The individual time of PRRSV infectious clones construction referred to the date of each publication.

[^3]: Genotype I and II PRRSV represents European and North America strains, respectively.

    ^c^ Sequences of full-genome cDNA clone rather than complete genome sequences of parental virus are listed.

[^4]: The genome area in which the restricted enzyme sites are introduced is indicated with brackets. The position where single mutations are introduced is given.

[^5]: Genome-length cDNA clones of pABV414 and pABV416 encode identical viral protein sequences except for one amino acid at position 1084 in ORF1a, which are a Pro in pABV414 and a Leu in pABV416.

[^6]: The abbreviation, NA I, in the genotype column represents genotype I PRRSV isolated in North America.

[^7]: N/A, not application. "nc" stands for no change.

[^8]: The abbreviation, ES, stands for the immunodominant B-cell epitopes identified in type I PRRSV.ES2-ES7 are identified in nsp2 encoding regions ([@bib0345]).

[^9]: NLS stands for the nuclear localization signal which mediates the nuclear localization of PRRSV N protein.

    ^c^ Ref. Seq. is the abbreviation of reference sequence, and GenBank accession numbers for each construct are provided.

[^10]: Symbols "↑" and "↓" indicate increased or reduced virus growth respectively.

[^11]: N/A, not application; nc, no change.

[^12]: Symbols "↑" and "↓" indicate increased or reduced virus growth respectively.

[^13]: N/A, not application. Whole represents the full sequence of a specific region.

[^14]: This section provides information of the regions replaced by the counterparts, including the virus, virus strains, the infectious clone used for swapping, and the exact position in which region is changed.

[^15]: The substituent section indicates the sequences used for substitutions.

[^16]: Infectious clone construct provided here includes both prototypes and modified constructs.
